CDX-011 Showing Incredible Result,s That One Drug Alone Is a Multibagger, besides other 5 great drus.
I don't believe for a second your a holder of BIOD, I think you just own MNKD and are trying to find something
so we will switch over. There was trading just in March and that's very common, I've seen companies with no inside trading done for years. Why would I buy MNKD that has had 2 CLR's and Pfizer who is the king of drugs came out with inhaler and they failed even though they put millions into marketing that MNKD doesn't even have for marketing.
Lazard Capital : Potential of SRPT: Commerical Opportunity $83 to $139 LINK
Jan 26, 2013 2:48 PM
(Remember This Article ? Lazard Capital Is One Of The Most Highly Credible Firms.I Posted This Because It Gives Everyone an Understanding of What SRPT Is Worth)
BARRON'S By: Andrew Barry
Article " High Flying Drug Stock Can Head Even Higher"
Barron's By: Andrew Barry Lazard Capital Markets analyst William Tanner wrote yesterday -- before the trial results were released -- that the US commercial opportunity for Sarepta with eteplirsen implied a stock price of $83 to $139 a share.
Seeking Alpha Market Currents 4/3/13
Netflix (NFLX) show House of Cards appears to be one of the favorites to land an Emmy nomination...
Wednesday, April 3, 8:33 AM ET
Netflix (NFLX) show House of Cards appears to be one of the favorites to land an Emmy nomination for drama this year with the award show's deadline rapidly approaching. A nomination - or even better a win - for a digital-only show could mark a turning point for the medium. The show can be streamed from Netflix forbinge-viewing but also has an afterlife with a Blu-ray release coming in June and new Android tweaks helping push Netflix content to Google TV and the PS3.
(Extreme Revalant To Earnings )
ARTICLE: BlackBerry Short Seller Squeeze Watch
By: George Kesarios
CEO Thorsten Heins has some good news ahead of the report. In an interview just two days ago in the Australian Financial Review, he said:
In the context of the financial viability of the company that is where I shake my head sometimes and wonder what everyone is talking about. The company has no debt, I will report pretty good cash position by the end of March in my earnings call, so I think we did a really diligent job in, not just keeping the company afloat, but also bringing it back to health.
So we have a given that the company will report a good cash position. This is very important because it tells us that the company will not have a problem building up inventory.
I don't know what short sellers are thinking, but they better adjust their thesis as to why they have shortedthis stock to begin with, because things might get out of hand and they might be "running for cover" very soon.